SRT 2104

Drug Profile

SRT 2104

Alternative Names: GSK-2245840; SRT-2104

Latest Information Update: 22 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sirtris
  • Developer GlaxoSmithKline
  • Class Antihyperglycaemics; Antipsoriatics; Small molecules
  • Mechanism of Action SIRT1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cardiovascular disorders; Chronic obstructive pulmonary disease; Inflammation; Muscular atrophy; Plaque psoriasis; Type 2 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Feb 2013 Sirtris completes a phase Ib trial in Ulcerative colitis in the US (NCT01453491)
  • 01 Dec 2012 Sirtris completes a phase I trial (in volunteers) in Plaque psoriasis in USA (NCT01702493)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top